|1.||Tang, Xi Can: 12 articles (01/2015 - 01/2002)|
|2.||Tang, X C: 10 articles (11/2001 - 01/2000)|
|3.||Zhang, Hai Yan: 9 articles (01/2015 - 01/2002)|
|4.||Doctor, Bhupendra P: 6 articles (12/2011 - 12/2003)|
|5.||Zhang, Hai-Yan: 4 articles (05/2014 - 08/2008)|
|6.||Yan, Han: 4 articles (09/2008 - 04/2004)|
|7.||Liu, Li: 3 articles (01/2015 - 03/2005)|
|8.||Wang, Mo: 3 articles (01/2015 - 01/2013)|
|9.||Gang, David R: 3 articles (07/2013 - 12/2004)|
|10.||Jiang, Hualiang: 3 articles (04/2013 - 11/2003)|
|1.||Alzheimer Disease (Alzheimer's Disease)
06/01/2011 - "In human clinical trials, Huperzine A resulted in cognitive improvement in patients with mild to moderate form of Alzheimer's disease (AD) showing its potential as a palliative agent in the treatment of AD. "
12/01/2004 - "Huperzine A (HupA) is reported to increase efficiency for learning and memory in animals, and it shows promise in the treatment of Alzheimer's disease (AD). "
09/01/1995 - "Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease."
11/04/2013 - "The aim of this study was to investigate constant current anodal iontophoresis of Huperzine A (HupA) in vitro and in vivo and hence to evaluate the feasibility of using electrically assisted delivery to administer therapeutic amounts of the drug across the skin for the treatment of Alzheimer's disease. "
07/01/2013 - "Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease."
09/24/1993 - "Huperzine A has been shown to be useful in the treatment of symptoms of dementia of the Alzheimer type. "
01/01/2013 - "Compared with placebo, Huperzine A showed a significant beneficial effect on the improvement of cognitive function as measured by Mini-Mental State Examination (MMSE) at 8 weeks, 12 weeks and 16 weeks, and by Hastgawa Dementia Scale (HDS) and Wechsler Memory Scale (WMS) at 8 weeks and 12 weeks. "
01/01/2008 - "However, Huperzine A was not superior to placebo in the improvement of general cognitive function measured by Hasegawa Dementia Scale (HDS) (WMD: 2.78; 95% CI -0.17 to 5.73, P = 0.06) and specific cognitive function measured by Weshler Memory Scale (WMS) (WMD = 6.64; 95% CI -3.22 to 16.50; P = 0.19). "
01/01/2008 - "These properties might qualify Huperzine A as a promising agent for treating dementia (including AD). "
06/09/2000 - "Our results strongly suggest that huperzine A has therapeutic potential for the treatment of dementia caused by cholinergic dysfunction and/or decrease of cerebral blood flow."
|3.||Memory Disorders (Memory Loss)
01/01/2004 - "Clinical trials of huperzine A in elderly patients with age-associated memory loss are underway in the US, and a phase II study funded by an NCI grant is being planned."
01/01/2015 - "It contains huperzine A, which has a protective effect against memory deficits in animal models; however, it is unclear if H. "
11/13/1995 - "Huperzine A (0.4-0.5 mg kg-1, i.p.) significantly ameliorated the AF64A-induced memory deficit. "
05/01/1991 - "[Drug evaluation of huperzine A in the treatment of senile memory disorders]."
04/01/2006 - "Oral administration of huperzine A (0.2 mg/kg, once per day, started 2 days before surgery and lasted for 7 days after surgery) markedly attenuated the memory deficits and neuronal damage. "
|4.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
08/15/2008 - "In this study, which used a rat middle cerebral artery occlusion (MCAO) model, the protective effects of huperzine A (HupA) against mitochondrial dysfunction and brain damage were investigated. "
08/15/2008 - "Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats."
08/01/2008 - "The present study investigated the protective effects of huperzine A in a rat model of transient focal cerebral ischemia created by middle cerebral artery occlusion (MCAO). "
11/09/2001 - "The protective effects of huperzine A on transient global ischemia in gerbils were investigated. "
11/09/2001 - "Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils."
11/09/2001 - "The ability of huperzine A to attenuate memory deficits and neuronal damage after ischemia might be beneficial in cerebrovascular type dementia."
09/13/2002 - "Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia."
06/09/2000 - "Daily oral administration of huperzine A produced a significant improvement of the deficit in the learning of the water maze task, beginning 28 days after ischemia, correlating to about 33-40% inhibition of acetylcholinesterase activity in cortex and hippocampus. "
|5.||Pyridostigmine Bromide (Pyridostigmine)
|6.||Nerve Growth Factors (Neurotrophins)
|8.||Cholinesterase Inhibitors (Anticholinesterases)
|9.||Proteins (Proteins, Gene)
|10.||physostigmine heptyl (MF 201)
|2.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|3.||Activities of Daily Living (ADL)